Sureda, Anna http://orcid.org/0000-0002-1238-6970
Carpenter, Paul A.
Bacigalupo, Andrea
Bhatt, Vijaya Raj http://orcid.org/0000-0003-2513-0533
de la Fuente, Josu http://orcid.org/0000-0002-0974-1249
Ho, Aloysius
Kean, Leslie http://orcid.org/0000-0003-0475-3926
Lee, Jong Wook http://orcid.org/0000-0003-2949-4166
Sánchez-Ortega, Isabel http://orcid.org/0009-0005-5519-9154
Savani, Bipin N. http://orcid.org/0000-0002-3304-9965
Schetelig, Johannes http://orcid.org/0000-0002-2780-2981
Stadtmauer, Edward A.
Takahashi, Yoshiyuki
Atsuta, Yoshiko http://orcid.org/0000-0003-4404-2870
Koreth, John
Kröger, Nicolaus http://orcid.org/0000-0001-5103-9966
Ljungman, Per http://orcid.org/0000-0002-8281-3245
Okamoto, Shinichiro
Popat, Uday http://orcid.org/0000-0002-7592-2224
Soiffer, Robert http://orcid.org/0000-0002-5810-1192
Stefanski, Heather E.
Kharfan-Dabaja, Mohamed A. http://orcid.org/0000-0001-7394-5185
Article History
Received: 1 February 2024
Revised: 8 February 2024
Accepted: 12 February 2024
First Online: 5 March 2024
Competing interests
: AS reports honoraria from Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, Alexion, consultancy for Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi Speaker’s Bureau for Takeda and Research Support for Takeda. VRB reports participating in the Safety Monitoring Committee for Protagonist, serving as an Associate Editor for the journal, Current Problems in Cancer, and as a contributor for BMJ Best Practice, and receiving consulting fees from Imugene, research funding (institutional) from MEI Pharma, Actinium Pharmaceutical, Sanofi U.S. Services, Abbvie, Pfizer, Incyte, Jazz, and National Marrow Donor Program, and drug support (institutional) from Chimerix for a trial. MAK-D reports grant/research support from Novartis, Bristol Myers Squibb, and Pharmacyclics and consultancy for Kite Pharma. JWL has received honoraria from Alexion and is a consultant to Alexion, AlloVir, Sanofi, Kyowa Kirin, and Samsung. A.B. reports as a speaker bureau for Therakos, Adienne, Sanofi, Jazz, Novartis, Pfizer, Equillium, MSDi. NK reports honoraria from Kite/Gilead, Jazz, MSD, Neovii Biotech, Alexion, MSD, Takeda, Novartis, Riemser, Pfizer, and BMS, and research support from Neovii, Riemser, Novartis and DKMS. RS reports consulting for Astellas, Amgen, Vor Biopharma, Smart Immune, Neovii, Bluesphere Bio, Jasper, data safety montoring board for BMS and board of directors, NMPD – be the match, USA -. JK reports serving on board and consults for Mallinckrodt, EMD Serono, Merck, Cugene, Cue Biotherapeutics, Biolojic Design, Gentibio, Nekonal, Equillium, and Amgen; and receives grants/research support from BMS, Miltenyi, Regeneron, Equillium, Amgen and Clinigen. YA reports consulting fees from JCR Pharmaceuticals Co., Ltd., and Kyowa Kirin Co., Ltd.; lecture fees from Otsuka Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd., Novartis Pharma KK, AbbVie GK; and honorarium from Meiji Seika Pharma Co, Ltd. LK is on the scientific advisory board for HiFiBio and Mammoth Biosciences, reports research funding from Magenta Therapeutics, BlueBird Bio, Bristol Myers Squibb, Novartis, Gilead, EMD Serono, and Regeneron Pharmaceuticals, consulting fees from Vertex Pharmaceuticals, grants and personal fees from Bristol Myers Squibb and her conflict of-interest with Bristol Myers Squibb is managed under an agreement with Harvard Medical School. PAC, EAS, BNS, AH, JS, YT, PL, UP, HS, JF, S-O, and I.S-O declare no conflict of interest.